BUFFALO GROVE, Ill., March 24, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Equities.com.
In the interview, Mr. Simes provides an overview of the Company's clinical programs, which include RES-529, a first-in-class PI3K/Akt/mTOR pathway inhibitor in development for wet age-related macular degeneration (AMD) and glioblastoma multiforme (GM), and RES-440, a "soft" anti-androgen compound for the treatment of acne vulgaris.
- The Company is currently finalizing formulation and preclinical studies for RES-529 and RES-440 ahead of a plan to initiate Phase 2 clinical trials in 2016.
- RES-529 for GM has been granted orphan drug designation and will be available orally for this indication, thereby providing ease of administration for patients.
- RES-529 for GM addresses a large market with a significant unmet medical need.
- The Company has a seasoned management team, including Sol J. Barer, Ph.D., Chairman of the Board of Directors, former Chairman and CEO of Celgene Corporation.
- The Company is well financed with approximately $22 million in cash as of December 31, 2014.
A link to the interview with Equities.com is available at: http://www.equities.com/media-gallery/475-restorgenex-corp-stephen-simes?category_id=78
About RestorGenex Corporation
RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information, please see: www.restorgenex.com.
Equities.com is the industry's most advanced, interactive financial community and comprehensive resource center for the "self-directed investors" and public issuer companies from around the globe. It offers its users the latest investment ideas, research analysis along with comprehensive exchange data via its platform.
Forward Looking Statements
Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about RestorGenex's plans to finalize formulation and preclinical studies during 2015 and to begin a Phase 2 trial in 2016 and other statements that are not historical in nature, particularly those that utilize terminology such as "plans," "will," "may," "expects," "future," "continue," "show promise," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause RestorGenex's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular risks and uncertainties include, among others, uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, RestorGenex's ability to license out its existing products and technologies and license in additional products and technologies and the terms of such licenses; and other risks and uncertainties described in RestorGenex's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K/A, subsequent quarterly reports on Form 10-Q and final prospectus dated July 31, 2014. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex's current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACT: The Trout Group LLC Marcy Nanus, 646-378-2927 firstname.lastname@example.org